Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 141 No. 0910 (2011)

Pre- and intra-operative mediastinal staging in non-small-cell lung cancer

  • D Lardinois
DOI
https://doi.org/10.4414/smw.2011.13168
Cite this as:
Swiss Med Wkly. 2011;141:w13168
Published
28.02.2011

Summary

Primary mediastinal lymph node staging is important to select properly patients who can benefit from an induction treatment. The accuracy of CT scan in the evaluation of mediastinal lymph nodes is low. Further staging can be omitted in patients with negative mediastinal PET in most of the cases. PET positive findings should always be histologically or cytologically confirmed. Endoscopic techniques are accurate minimally invasive techniques mostly used to confirm a PET-positive finding but not for complete mediastinal staging. Mediastinoscopy is an invasive technique which provides a complete statging of the upper mediastinum. At least one ipsilateral, one contralateral and the subcarinal nodes should be routinely biopsied. Restaging of the mediastinum after induction treatment is necessary to select the patients who can benefit from surgery. There are no imaging techniques which can accurately determine the biological response of the tumour to the induction treatment. Neither CT, PET or PET-CT seem good enough to make further therapeutic decisions, based on their results. The accuracy of PET in mediastinal restaging is not optimal, mainly due to its low sensitivity. Fusion images with PET-CT seem to improve the results with a very favourable sensitivity, specificity and accuracy. An invasive technique providing cytohistological information is necessary. For restaging techniques, endoscopic techniques or surgical invasive techniques can be used. If they yield a positive result, definitive nonsurgical treatment seems to be indicated in most patients. Remediastinoscopy has proven to be feasible but due to adhesions and fibrosis, the intervention is technically challenging.

The technique of lymph-node assessment during surgery for non-small-cell lung cancer (NSCLC) is not standardised to date. Accurate intra-operative staging is necessary to compare the results from different institutions and to conduct multi-institutional trials. Systematic mediastinal lymph-node dissection is recommended in all cases for complete resection of NSCLC and improves pathologic staging and the prospect for adjuvant therapy. The role of mediastinal lymphadenectomy regarding overall survival and local control remains controversial but systematic lymph-node dissection might be associated with a better outcome in stage I NSCLC. Lobe-specific systematic nodal dissection is acceptable for peripheral squamous T1 tumours, if hilar and interlobar nodes are negative on frozen section studies.

References

  1. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003;21:1752–9.
  2. Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg. 2001;70:1826–31.
  3. Lorent N, De Leyn P, Lievens Y, et al. Long-term survival of surgically staged IIIA-N2 non-small cell lung cancer treated with surgical combined modality approach: analysis of a 7-year experience. Ann Oncol. 2004;15:1645–53.
  4. Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, et al., North American Lung Cancer Intergroup. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by surgical resection for stage IIIA (pN2) nonsmall cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). The Oncologist. 2006;11:43.
  5. Van Meerbeeck JP, Kramer G, Van Schil PE, Legrand C, Smit EF, Schramel FM, et al., EORTC-Lung Cancer Group. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 nonsmall cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941). The Oncologist. 2006;11:42–3.
  6. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest. 2003;123:137S–146S.
  7. Martin-Ucar AE, Chetty GK, Vaughan R, Waller DA. A prospective audit evaluating the role of video-assisted cervical mediastinoscopy (VAM) as a training tool. Eur J Cardiothorac Surg. 2004; 26:393–5.
  8. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718–23.
  9. Lardinois D, De Leyn P, Van Schil PE, Rami Porta R, Waller, Passlick B, et al. ESTS guidelines for intraoperative lymph node staging in non-small-cell lung cancer. Eur J Cardiothorac Surg. 2006;30:787–92.
  10. Toloza EM, Harpole L, Detterbeck F. Invasive staging of non-small cell lung cancer: A review of the current evidence. Chest. 2003;123:157S–166S.
  11. Lardinois D, Schallberger A, Betticher D, Ris HB. Postinduction video-mediastinoscopy is as accurate and safe as video-mediastinoscopy in patients without pretreatment for potentially operable non-small cell lung cancer. Ann Thorac Surg. 2003;75:1102–6.
  12. Mouroux J, Venissac N, Alifano M. Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer. Ann Thorac Surg. 2001;72:1698–704.
  13. De Leyn P, Lerut T. Videomediastinoscopy, in Yim AP, Hazelrigg SR, Izzat MB, Landreneau RJ, Mack MJ, Naunheim KS (ed). Minimal access in cardiothoracic surgery. WB Saunders. 2000;169–74.
  14. Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT. Radiology. 1999;213:530–6.
  15. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol. 2001;2:659–66.
  16. Hellwig D, Ukena D, Paulsen F, et al. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000 (in German). Pneumologie. 2001;55:367–77.
  17. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139:879–92.
  18. Birim O, Kappetein AP, Stijnen T, et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in non-small cell lung cancer. Ann Thorac Surg. 2005;79:375–82.
  19. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: A prospective analysis of 50 cases. Chest. 1997;112:1480–6.
  20. Verhaghen AT, Bootsma GP, Tjan-Heijnen VCG, van der Wilt GJ, Cox AL, Brouwer MHJ, et al. FDG-PET in staging lung cancer. How does it change the algorithm? Lung cancer. 2004;44:175–81.
  21. Lardinois D, Weder W, Hany TF, et al. Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500–7.
  22. Holty JEC, Kuschner WG, Gould MK. Accuracy of transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: a meta-anlysis. Thorax. 2005;60:949–55.
  23. Detterbeck FC, Jones DR, Parker Jr LA. Intrathoracic staging. In: Detterbeck FC, Rivera MP, Socinski MA, Roseman JG (Editors). Diagnosis and treatment of lung cancer. An evidence-based guide for the practicing clinician. WB Saunders Company, Philadelphia, 2001;73–93.
  24. Annema JT, Verteegh MI, Veselic M, Voigt P, Rabe KF. Endoscopic ultrasound fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. JCO. 2005;23:8357–61.
  25. Kramer H, Groen HJM. Current concepts in the mediastinal lymph node staging of nonsmall cell lung cancer. Ann Thorac Surg. 2003;238:180–8.
  26. Martin J, Ginsberg RJ, Venkatraman ES. Long-term results of combined-modality therapy in resectable non-small cell lung cancer. J Clin Oncol. 2002;15:1989–95.
  27. De Leyn P, Stoobants S, Dewever W, Lerut T, Coosemans W, Decker G, et al. Prospective comparative study of integrated PET-CT versus re-mediastinoscopy in the assessment of residual mediastinal disease after induction chemotherapy for mediastinoscopy proven stage IIIa-N2 non-small cell lung cancer. JCO, 2006
  28. Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, et al. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg. 2000;70:391–5.
  29. Pitz CCM, Maas KW, Van Swieten HA, et al. Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer. Ann Thorac Surg. 2002;74:164–9.
  30. Van Schil P, Van Der Schoot J, Poniewierski J, et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer. 20022;37:281–5.
  31. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg. 2002;73:259–66.
  32. Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002;35:179–87.
  33. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg. 2003;15:938–44.
  34. Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg. 2004;77:254–9.
  35. Hellwig D, Graeter TP, Ukena D, et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg. 2004;128:892–9.
  36. Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, et al. Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron emission tomography/computed tomography in non-smal-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancver Res. 2006;12:97–106.
  37. Annema JT, Veselic M, Versteegh MIM, Willems LNA, Rabe KF. Mediastinal restaging: EUS-FNA offers a new perspective. Lung Cancer. 2003;42:311–8.
  38. Herth FJ, Annema JT, Eberhardt R, Yasufuku K, Ernst A, Krasnik M, Rintoul RC. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. J Clin Oncol. 2008;26:3346–50.
  39. Silverberg SG, Connolly JL, Dabbs D, Muro-Cacho CA, Page DL, Ray MB, Wick MR. Association of directors of anatomic and surgical pathology. Recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. Am J Clin Pathol. 2001;115:799–801.
  40. Goldstraw P. Report on the international workshop on intrathoracic staging. London. October 1996. Lung Cancer. 1997;18:107–11.
  41. Graham A, Chan K, Pastorino U, Goldstraw P. Systematic nodal dissection in the intrathoracic staging of patients with non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1999;117:246–51.
  42. Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005;49:25–33.
  43. Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006;30:787–92.
  44. Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H. Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg. 1999;16:S17–S24.
  45. Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, et al., Japanese Clinical Oncology Group. J Thorac Cardiovasc Surg. 2001;122:803–8.
  46. De Leyn P, Vansteenkiste J, Cuypers P, Deneffe G, Van Raemdonck D, Coosemans W, et al. Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT-scan. Eur J Cardiothorac Surg. 1997;12:706–12.
  47. Verhagen A, Bootsma G, Tjan-Heijnen V, van der Wilt G, Cox A, Brouwer M, et al. FDG-PET in staging lung cancer. How does it change the algorithm? Lung Cancer. 2004;44:175–81.
  48. GCCB-S (Grupo Cooperativo de Carcinoma Broncogencio de la Sociedad Espanola de Neumologia y Cirugia Toracica). Intraoperative lymph node staging in bronchogenic carcinoma surgery. Consensus report. Arch Bronconeumol. 2001;37:495–503.
  49. Fry WA. Assessment of operability and respectability in lung cancer. Malignant tumors of the lung. Springer. 2004;179–82.
  50. Izbicki JR, Passlick B, Karg O, Bloechle C, Pantel K, Knoefel WT, Thetter O. Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. Ann Thorac Surg. 1995;59:209–14.
  51. Keller SM, Adak S, Wagner H, Johnson DH. Mediastinal lymph node dissection improves survival in patients with stages II and IIIA NSCLC. Ann Thorac Surg. 2000;70:358–66.
  52. Wu Y, Huang Z, Wang S, Yang X, Ou W. A randomized trial of systematic nodal dissection in resectable NSCLC. Lung Cancer. 2002;36:1–6.
  53. Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80:268–74.
  54. Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, et al.; Eastern Cooperative Oncology Group. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg. 2004;128:130–7.
  55. Wright G, Manser RL, Byrnes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax. 2006;61: 597–603.